{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:47:17Z","timestamp":1777909637408,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2010,7,24]],"date-time":"2010-07-24T00:00:00Z","timestamp":1279929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Ocular Pharmacology and Therapeutics"],"published-print":{"date-parts":[[2010,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>The effective management of dry eye must include a clinically meaningful reduction in ocular staining. Evaluations of corneal and conjunctival staining and other ocular symptoms of dry eye were conducted for a new formulation of polyethylene glycol 400\/propylene glycol-based lubricant eye drops containing hydroxypropyl guar as a gelling agent (Test Product) in comparison to Optive\u2122 Lubricant Eye Drops (Control Product) in adult patients with dry eye.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>One hundred thirteen patients, 18 years of age and older, with dry eye were enrolled in a prospective, double-masked, multisite, parallel-group study. After a 2-week run-in period during which patients administered aqueous saline eye drops 4 times daily (QID) in each eye, patients were randomized (1:1) to receive either Test Product or Control Product to be administered QID for 6 weeks. Efficacy and safety were evaluated by corneal and conjunctival staining scores, tear film breakup time, assessments of ocular symptoms, ocular surface disease index (OSDI) scores, dry eye treatment satisfaction, visual function-14 questionnaires, and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The intent-to-treat data set included 105 patients randomized to Test Product (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200952) or Control Product (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      \u2009=\u200953). Patients primarily were between the ages of 18\u201364 years (70.5%), female (73.3%), white (93.3%), and not Hispanic (81.9%). Patients in the Test Product group exhibited significantly lower mean corneal staining scores than the Control Product group at day 14 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.0009) and day 42 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.0106), and significantly lower mean conjunctival staining scores at day 28 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.0475) and day 42 (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.0009). Patients in both treatment groups reported significant reductions in the mean scores for the ocular symptoms of dryness, gritty\/sandy feeling, and burning (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009\u2264\u20090.0021 for all comparisons to baseline). Lastly, a significantly lower OSDI score than baseline was reported at day 42 by patients in both the Test Product (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u20090.0013) and Control Product (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009&lt;\u20090.0001) groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The results of this study indicate that the Test Product significantly reduced corneal and conjunctival staining, indicating a reduction in disease severity. Evaluations of ocular staining scores provide clinically meaningful evidence of dry eye severity and are an important indicator of dry eye disease progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/jop.2010.0025","type":"journal-article","created":{"date-parts":[[2010,7,24]],"date-time":"2010-07-24T08:20:49Z","timestamp":1279959649000},"page":"347-353","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy in Patients with Dry Eye After Treatment with a New Lubricant Eye Drop Formulation"],"prefix":"10.1177","volume":"26","author":[{"given":"William F.","family":"Davitt","sequence":"first","affiliation":[{"name":"Corona Research Consultants"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bloomenstein","sequence":"additional","affiliation":[{"name":"Schwartz Laser Eye Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mike","family":"Christensen","sequence":"additional","affiliation":[{"name":"Alcon Research Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna E.","family":"Martin","sequence":"additional","affiliation":[{"name":"Alcon Research Ltd."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2010,7,24]]},"reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00140068-200301001-00027"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.12.1359"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70082-4"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.9.1264"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.6.819"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(03)00218-6"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9394(14)71688-5"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00055735-200408000-00004"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2005.12.003"},{"key":"e_1_3_3_11_2","first-page":"S102","article-title":"Prevalence, burden, and pharmacoeconomics of dry eye disease","volume":"14","author":"Pflugfelder S.C.","year":"2008","unstructured":"Pflugfelder S.C. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am. J. Manag. Care, 14:S102\u2013S106. 2008.","journal-title":"Am. J. Manag. Care"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70085-X"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70081-2"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-008-0112-0"},{"key":"e_1_3_3_15_2","first-page":"S79","article-title":"Dry eye disease: pathophysiology, classification, and diagnosis","volume":"14","author":"Perry H.D.","year":"2008","unstructured":"Perry H.D. Dry eye disease: pathophysiology, classification, and diagnosis. Am. J. Manag. Care, 14:S79\u2013S87. 2008.","journal-title":"Am. J. Manag. Care"},{"key":"e_1_3_3_16_2","unstructured":"Optive (TM). Information for practitioners. www.allergan.com. 2009 February 12."},{"key":"e_1_3_3_17_2","first-page":"33","article-title":"Treatment of patients with keratoconjunctivitis sicca with Optive: results of a multicenter, open-label observational study in Germany","volume":"3","author":"Kaercher T.","year":"2009","unstructured":"Kaercher T., , Buchholz P., , Kimmich F. Treatment of patients with keratoconjunctivitis sicca with Optive: results of a multicenter, open-label observational study in Germany. Clin. Ophthalmol., 3:33\u201339. 2009.","journal-title":"Clin. Ophthalmol."},{"key":"e_1_3_3_18_2","first-page":"221","article-title":"Report of the National Eye Institute\/Industry workshop on clinical trials in dry eyes","volume":"21","author":"Lemp M.A.","year":"1995","unstructured":"Lemp M.A. Report of the National Eye Institute\/Industry workshop on clinical trials in dry eyes. CLAO J., 21:221\u2013232. 1995.","journal-title":"CLAO J."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.118.5.615"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1994.01090170074026"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1076\/ceyr.28.1.55.23495"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-0124(12)70084-8"}],"container-title":["Journal of Ocular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/jop.2010.0025","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2010.0025","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/jop.2010.0025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T14:36:04Z","timestamp":1777646164000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/jop.2010.0025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7,24]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8,1]]}},"alternative-id":["10.1089\/jop.2010.0025"],"URL":"https:\/\/doi.org\/10.1089\/jop.2010.0025","relation":{},"ISSN":["1080-7683","1557-7732"],"issn-type":[{"value":"1080-7683","type":"print"},{"value":"1557-7732","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,24]]}}}